Omontys (peginesatide) Injection
Attention Kidney Patients and Healthcare Providers: Affymax, Inc. and Takeda Pharmaceuticals Company Limited recalled all lots of the anemia treatment for kidney dialysis patients, Omontys (peginesatide) Injection, due to reports of serious adverse events and death. The companies issued the recall on Feb. 23, 2012.
Deaths Linked to Dialysis Treatment
Since Omontys has been on the market, it has been used to treat more than 25,000 adult patients on dialysis with anemia due to due to chronic kidney disease. According to Bloomberg, there have been 19 reports of anaphylaxis from U.S. dialysis centers. Three of the cases resulted in death. Reports show that about .2 percent of patients have required medical intervention following a reaction.
According to reports, all fatal reactions occurred within 30 minutes of administering the first dose intravenously. No reports of such reactions have been made after subsequent dosing or in patients who have finished their dialysis treatment. The cause of the reactions has not been identified. According to Bloomberg, Affymax is analyzing data from patients who have experienced reactions to the medication to find out why.
The patients that have experienced hypersensitivity to the injections have required prompt medical attention and in some cases hospitalization. According to the recall, no new patients should be treated with Omontys.
Don’t Delay! Call Clay!
If you or someone you love suffered a serious reaction to an injection of Omontys, don’t delay! Call Clay! We are available to review potential lawsuits on behalf of patients who have suffered from a reaction as well as the families of those who have died as a result of an injection.